Jerrell Shelton - Nov 21, 2024 Form 4 Insider Report for Cryoport, Inc. (CYRX)

Role
President, CEO, Director
Signature
/s/ Jerrell Shelton
Stock symbol
CYRX
Transactions as of
Nov 21, 2024
Transactions value $
-$60,030
Form type
4
Date filed
11/25/2024, 07:00 PM
Previous filing
Nov 20, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CYRX Common Stock Options Exercise $284K +59.2K +8.18% $4.80 782K Nov 21, 2024 Direct F1
transaction CYRX Common Stock Sale -$325K -50K -6.39% $6.51 732K Nov 21, 2024 Direct F1, F2
transaction CYRX Common Stock Options Exercise $129K +26.9K +3.67% $4.80 759K Nov 22, 2024 Direct F1
transaction CYRX Common Stock Sale -$148K -22.8K -3.01% $6.47 736K Nov 22, 2024 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CYRX Stock Option (right to buy) Options Exercise $0 -59.2K -68.77% $0.00 26.9K Nov 21, 2024 Common Stock 59.2K $4.80 Direct F1, F4
transaction CYRX Stock Option (right to buy) Options Exercise $0 -26.9K -100% $0.00 0 Nov 22, 2024 Common Stock 26.9K $4.80 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The transactions reported in this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 15, 2024.
F2 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.31 to $6.66, inclusive. The reporting person undertakes to provide to Cryoport, Inc., any security holder of Cryoport, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.34 to $6.60, inclusive. The reporting person undertakes to provide to Cryoport, Inc., any security holder of Cryoport, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 1/48 of the options vested on the 18th of each month for forty-eight months beginning on January 18, 2015.